We thus explored sensitivity to ferroptotic mediators and explored mechanisms leading to resistance to ferroptosis in luminal hormone receptor (HR)-positive BC cell lines to identify effective combination therapy approaches for this BC population. The gene discussed is NR4A1; the disease is breast cancer.